Orelabrutinib plus chemo for newly diagnosed DLBCL
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if adding orelabrutinib (a targeted pill) to standard chemotherapy, with or without a stem cell transplant, works better for people with a new diagnosis of diffuse large B-cell lymphoma. It may help patients who have a higher risk of the lymphoma coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a new diagnosis of CD20-positive diffuse large B-cell lymphoma (a common type of lymphoma).
- Your IPI score (a measure of risk) is 2, 3, 4, or 5.
- You are in good enough health to walk around and take care of yourself (ECOG score 0-2).
- Your heart, kidneys, and liver are working well based on standard tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called orelabrutinib given with standard chemotherapy for a specific subtype of diffuse large B-cell lymphoma (DLBCL) called MCD. The treatment aims to improve outcomes and is followed by a maintenance phase with orelabrutinib alone.
This trial tests a new combination of drugs for people newly diagnosed with an aggressive type of lymphoma called diffuse large B-cell lymphoma (DLBCL). The combo includes orelabrutinib plus standard chemo-immunotherapy, and may help improve outcomes for those at intermediate or high risk.
This trial tests a combination of two targeted drugs (orelabrutinib and obinutuzumab) as a first treatment for marginal zone lymphoma that has returned or progressed after local therapy. The goal is to see if this combination works better than current options.
This trial tests whether adding a targeted therapy called orelabrutinib to standard chemotherapy (R-CHOP) helps people with a specific type of fast-growing lymphoma (CD5-positive DLBCL). If you have this lymphoma and haven't had a BTK inhibitor before, this combination might work better than chemo alone.
This trial tests a combination of targeted therapy (Orelabrutinib) plus standard chemotherapy (Pola-R-CHP) for people with untreated non-GCB diffuse large B-cell lymphoma. The goal is to see if this new mix works better than the usual treatment.
This trial tests a new pill (orelabrutinib) combined with a standard chemotherapy regimen (called BG) as your first treatment for CLL or SLL. The goal is to see if this combination works well and is safe for people like you who have not been treated before.
Hear when a new DLBCL - Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.